Itraconazole for Esophageal Cancer Treatment
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Recruiting
Phase 2
Interventional Study
Esophagus Adenocarcinoma
Esophagus Squamous Cell Carcinoma
Gastroesophageal Junction Adenocarcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 78 (estimated)
- Sponsor
- Dallas VA Medical Center · Federal
Who this trial is looking for
This trial is looking for patients with localized esophageal or gastroesophageal junction cancer. If you join, you will receive itraconazole after standard cancer treatments.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with localized esophageal cancer
- I have been diagnosed with localized gastroesophageal junction cancer
You may not be able to join if
- I am unwilling or unable to provide informed consent
- I have a QTc greater than 450ms
- I have a history of symptomatic congestive heart failure
- I have liver function test results greater than 3 times the normal limit
- I am pregnant
- I have a known allergy to itraconazole
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
Esophageal cancer, which has a low 5-year overall survival rate for all stages (\<20%) , is increasing in incidence. Previous studies have shown that the Hedgehog (Hh) and AKT signaling pathways are activated in a significant proportion of esophageal cancers. Itraconazole, a widely used anti-fungal medication, has been shown to inhibit various pathways involved in esophageal cancer tumorigenesis i…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients diagnosed with localized (locoregional) esophageal cancer
* Patients diagnosed with localized (locoregional) gastroesophageal junction cancer
Exclusion Criteria:
* Patients unwilling or unable to provide informed consent
* Patients with QTc\>450ms
* Patients with a …
Contacts